Integral membrane proteins

AmbioPharm Inc. Working with University of California Davis to Develop Non-Opioid Peptide-Based Pain Therapeutics

Retrieved on:

Tuesday, July 20, 2021

It has a variety of causes and negatively impacts the quality of life of those who are affected.

Key Points:

It has a variety of causes and negatively impacts the quality of life of those who are affected.
The natural world is full of venomous creatures whose venoms are full of potential drug candidates, for treating conditions such as diabetes, pain, and cancer.
Isolation of certain sodium channel blocking peptides from spider venoms have been shown to function as potential therapeutics for pain alleviation.
Targeting the voltage-gated ion channels may yield useful treatments in an array of disorders, including pain, migraines, epilepsy, neurological disorders, and more.

Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)

Retrieved on:

Friday, June 18, 2021

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of company information on Neuromyelitis Optica Spectrum Disorder (NMOSD) in three oral sessions during the 7th Congress of the European Academy of Neurology (EAN), June 19 -22, 2021.

Key Points:

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of company information on Neuromyelitis Optica Spectrum Disorder (NMOSD) in three oral sessions during the 7th Congress of the European Academy of Neurology (EAN), June 19 -22, 2021.
Presentations will discuss information from the open-label extension period (OLP) of the pivotal N-MOmentum trial for people living with NMOSD.
Title: Long term safety outcomes in neuromyelitis optica spectrum disorder: N-MOmentum trial
Title: Long term efficacy outcomes in neuromyelitis optica spectrum disorder: N-MOmentum trial
NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes.
Baranello RJ, Avasarala, JR. Neuromyelitis optica spectrum disorders with and without aquaporin 4 antibody: Characterization, differential diagnosis, and recent advances.

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

Retrieved on:

Thursday, June 10, 2021

Integral membrane proteins, Membrane proteins, Transmembrane proteins, Single-pass transmembrane proteins, Transmembrane receptors, Neuropilin 2, Neuropilin, Semaphorin, E-selectin, aTyr Pharma

The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.

Key Points:

The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.
Class 3 Semaphorins are an important set of NRP2 ligands, with recent data implicating their role in sustaining chronic inflammation.
Details of the abstract and poster presentation are as follows:
The poster is also available on the aTyr website.
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults

Retrieved on:

Tuesday, June 1, 2021

Branches of biology, Biology, Neurophysiology, Electrophysiology, Integral membrane proteins, Geriatrics, Rehabilitation medicine, Sarcopenia, Ion channel, Neuromuscular junction

NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel and has already demonstrated that ClC-1 inhibition can strengthen neuromuscular transmission and ultimately skeletal muscle function.

Key Points:

NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel and has already demonstrated that ClC-1 inhibition can strengthen neuromuscular transmission and ultimately skeletal muscle function.
This study is intended to establish whether NMJ transmission deficits occur in sarcopenic individuals, and to investigate whether these deficits correlate with reduced physical performance.
Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: This is the first clinical study that NMD Pharma has coordinated in older adults with sarcopenia.
We are grateful to the world-leading clinical teams in Ohio, and their prospective study participants, for making this study possible.

NMD Pharma Initiates an Observational Pilot Study Investigating the Effects of Sarcopenia on Neuromuscular Transmission in Older Adults

Retrieved on:

Tuesday, June 1, 2021

Branches of biology, Biology, Neurophysiology, Electrophysiology, Integral membrane proteins, Geriatrics, Rehabilitation medicine, Sarcopenia, Ion channel, Neuromuscular junction

NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel and has already demonstrated that ClC-1 inhibition can strengthen neuromuscular transmission and ultimately skeletal muscle function.

Key Points:

NMD Pharma is developing first-in-class small molecule inhibitors of the muscle specific chloride ion channel, the ClC-1 ion channel and has already demonstrated that ClC-1 inhibition can strengthen neuromuscular transmission and ultimately skeletal muscle function.
This study is intended to establish whether NMJ transmission deficits occur in sarcopenic individuals, and to investigate whether these deficits correlate with reduced physical performance.
Thomas Holm Pedersen, Chief Executive Officer of NMD Pharma, said: This is the first clinical study that NMD Pharma has coordinated in older adults with sarcopenia.
We are grateful to the world-leading clinical teams in Ohio, and their prospective study participants, for making this study possible.

Saniona to Host Research and Development (R&D) Day on Leveraging Ion Channel Targeting Expertise for Rare Diseases

Retrieved on:

Wednesday, May 12, 2021

Branches of biology, Biology, Electrophysiology, Integral membrane proteins, Ion channels, Cell communication, Neurochemistry, Pharmacology, Potassium channel

Presenters will include members of Saniona\xe2\x80\x99s research team and executive management, as well as ion channel Key Opinion Leader (KOL) Heike Wulff, Ph.D., Professor of Pharmacology, University of California (UC) Davis School of Medicine.

Key Points:

Presenters will include members of Saniona\xe2\x80\x99s research team and executive management, as well as ion channel Key Opinion Leader (KOL) Heike Wulff, Ph.D., Professor of Pharmacology, University of California (UC) Davis School of Medicine.
Dr. Wulff\xe2\x80\x99s research is focused on potassium channel pharmacology and the design of new ion channel modulating drugs and tool compounds.
Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development.
Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and is building its corporate office in the Boston, Massachusetts area, U.S.

GlycoMimetics to Report First Quarter Financial Results on May 3, 2021

Retrieved on:

Monday, April 26, 2021

Biotechnology, General Health, Health, Pharmaceutical, Oncology, Proteins, Branches of biology, Selectins, Integral membrane proteins, CXCR4, E-selectin, Conference call, Dial

b"GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021, at 8:30 a.m. ET.\nThe dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 9891637.

Key Points:

b"GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that it will host a conference call and webcast to report first quarter financial results on Monday, May 3, 2021, at 8:30 a.m. ET.\nThe dial-in number for the conference call is (844) 413-7154 for domestic participants or (216) 562-0466 for international participants, with participant code 9891637.
Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease.
GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist.
GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region.

Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting

Retrieved on:

Saturday, April 10, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Proteins, Branches of biology, Selectins, Integral membrane proteins, Chemokine receptors, Clusters of differentiation, CXCR4, E-selectin, American Association for Cancer Research, GMI-1359, GlycoMimetics, Inc.

The presentation will be made at the American Association of Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually on April 10-15 and May 17-21.

Key Points:

The presentation will be made at the American Association of Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually on April 10-15 and May 17-21.
The clinical poster concludes that GMI-1359 demonstrated an acceptable safety and tolerability profile in the patients treated to date.
These findings on immune cell redistributions strongly suggest the induction of a more favorable anti-tumor environment following GMI-1359 administration.
GlycoMimetics has an ongoing Phase 1b clinical trial evaluating its wholly-owned drug candidate GMI-1359, a combined CXCR4 and E-selectin antagonist.

GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model

Retrieved on:

Saturday, April 10, 2021

Biotechnology, Pharmaceutical, Health, Oncology, Clusters of differentiation, Branches of biology, Integral membrane proteins, Transmembrane proteins, E-selectin, CXCR4, PD-L1, GMI-1757, GlycoMimetics, Inc.

The study demonstrates that GMI-1757 significantly improved anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model.

Key Points:

The study demonstrates that GMI-1757 significantly improved anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model.
Microscopic evaluations also showed that in groups treated with GMI-1757 both the incidence and area of intratumoral fibrosis were markedly reduced.
Investigations will continue on GMI-1757s impact when combined with immune modulators where fibrosis and restricted host cell infiltration negatively impact tumor response.
GlycoMimetics has an ongoing Phase 1b clinical trial evaluating its wholly-owned drug candidate GMI-1359, a combined CXCR4 and E-selectin antagonist.

New UPLIZNA® (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology’s 73rd Annual Meeting

Retrieved on:

Monday, April 5, 2021

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data will be presented at the American Academy of Neurologys 73rd Annual Meeting, which will be held virtually April 17-22, 2021.

Key Points:

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data will be presented at the American Academy of Neurologys 73rd Annual Meeting, which will be held virtually April 17-22, 2021.
UPLIZNA is the first and only FDA-approved B-cell depleter for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD.
UPLIZNA is contraindicated in patients with:
Infusion Reactions: UPLIZNA can cause infusion reactions, which can include headache, nausea, somnolence, dyspnea, fever, myalgia, rash or other symptoms.
2019;6(4):e580
Baranello RJ, Avasarala, JR. Neuromyelitis optica spectrum disorders with and without aquaporin 4 antibody: Characterization, differential diagnosis, and recent advances.